Advances in Phactr1 related polyvascular disease: from bench to bedside
Ma Xiaoxuan,
Chen Meijie,
Weng Jianping,
Xu Suowen
Affiliations
Ma Xiaoxuan
Laboratory of Metabolics and Cardiovascular Diseases, The First Affiliated Hospital of USTC, University of Science and Technology, Hefei 230027, Anhui, China
Chen Meijie
Laboratory of Metabolics and Cardiovascular Diseases, The First Affiliated Hospital of USTC, University of Science and Technology, Hefei 230027, Anhui, China;School of Life Sciences, Zhengzhou University, Zhengzhou 450001, Henan, China
Weng Jianping
Laboratory of Metabolics and Cardiovascular Diseases, The First Affiliated Hospital of USTC, University of Science and Technology, Hefei 230027, Anhui, China
Xu Suowen
Laboratory of Metabolics and Cardiovascular Diseases, The First Affiliated Hospital of USTC, University of Science and Technology, Hefei 230027, Anhui, China
Recent genome-wide association studies have identified Phactr1 as a risk gene associated with polyvascular diseases. However, it remains elusive how Phactr1 is involved in the pathogenesis of vascular diseases. More recently, mounting evidence has suggested that PHACTR1 as an actin and protein phosphatase 1 binding protein, regulates endothelial proliferation, apoptosis, migration and tube formation, affects polarization in macrophages, and aggravates calcification in vascular smooth muscle cells. This paper focuses on the correlation between Phactr1 and polyvascular disease, and the molecular mechanism of Phactr1 in regulating atherosclerosis. We thus provided an overview of the role and therapeutic potential of Phactr1 in the progression of polyvascular disease.
